We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Data Science & Analytics/An industrial case study: QbD to accelerate time-to-market of a drug product

Checking your access to this record.

Abstract & Overview

Abstract The use of a Quality by Design (QbD) approach in the development of pharmaceutical products is known to bring many advantages to the table, such as increased product and process knowledge, robust manufacturing processes, and regulatory flexibility regarding changes during the commercial phase. However, many companies still adhere to a more traditional pharmaceutical process development—in some cases due to the difficulty of going from a theoretical view of QbD to its actual application. This article presents a real-world case study for the development of an industrial pharmaceutical drug product (oral solid dosage form) using the QbD methodology, demonstrating the activities involved and the gains in obtaining systematic process and product knowledge.

Cite this record

Madalena Testas, Tiago da Cunha Sais, Leonardo Piccoli Medinilha, Katia Nami Ito Niwa, Lucas Sponton de Carvalho, Silvia Duarte Maia, et al. (2021). An industrial case study: QbD to accelerate time-to-market of a drug product. AAPS Open, 7(1). https://doi.org/10.1186/s41120-021-00047-w

Copy in another style

Testas, M., Sais, T. D. C., Medinilha, L. P., Niwa, K. N. I., Carvalho, L. S. D., Maia, S. D., Flores, A., Braz, L. P., Menezes, J. C. D., & Yamakawa, C. Y. (2021). An industrial case study: QbD to accelerate time-to-market of a drug product. AAPS Open, 7(1). https://doi.org/10.1186/s41120-021-00047-w
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.